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Background: Among the patients with established coronary artery diseases, obese patients tend to have a more
favorable prognosis, which is called as obesity paradox. Interestingly, mildly obese patients who underwent
coronary revascularization had a lower risk of bleeding. In this context, we have investigated the association
between obesity and hemorrhagic transformation (HTf) after acute ischemic stroke.
Methods: A total of 365 patients with first-ever acute ischemic stroke were included in this study. Demographic,
clinical and radiological information was collected and HTf was evaluated through follow-up T2*-weighted
gradient-recalled echo MRI performed usually within 1 week after occurrence of stroke. Body mass index was
calculated, and obesity was defined using the World Health Organization Western Pacific Regional Office criteria.
Results: The HTf was identified in 59 patients (16.2%). As the severity of obesity increased, the occurrence of HTf
decreased. Compared with the normal weight group and after controlling possible confounders including acute
and previous treatment, stroke severity and subtype, the risk of HTf decreased significantly in the obese group
(odds ratio, 0.39; 95% confidence interval, 0.17-0.87).
Conclusions: The better outcome for HTf seen in obese patients suggests the existence of a “bleeding-obesity
paradox” in acute ischemic stroke.
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Hemorrhagic transformation (HTf) frequently occurs after
ischemic stroke with or without thrombolytic treatment
[1,2]. It was known that HTf after acute ischemic
stroke was associated with poor outcome and delayed the
initiation of proper anticoagulation treatment for stroke
with cardioembolism [3]. Although certain studies have
demonstrated the association between old age [4], high
systolic pressure [5], or thrombolytic treatment [6] with
HTf, the predictive factor for HTf after acute ischemic
stroke is still elusive.
Obesity affects more than a billion adults worldwide,
and is implicated as one of the major risk factors of
cardiovascular diseases [7,8]. However, in patients with
established coronary artery diseases, obese patients tend* Correspondence: sb0516@snu.ac.kr
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reproduction in any medium, provided the orto have a more favorable prognosis, which is called
as obesity paradox [8,9]. Interestingly, according to a
recent study, mild obese patients who underwent
coronary revascularization had a lower incidence of
periprocedural bleeding, and the authors in that study
called this phenomenon as “bleeding-obesity paradox” [10].
In ischemic stroke, HTf occurs after extravasation of
blood over damaged cerebral vascular endothelium and is
more directly associated with disease itself than bleeding
after coronary revascularization [11]. However, few studies
have investigated the effects of obesity on the bleeding after
ischemic stroke. In this context, we sought to investigate
the association between obesity and HTf, and assessed
whether “bleeding-obesity paradox” exists in acute ischemic
stroke.Methods
A total of 744 first-ever acute ischemic stroke patients who
had been admitted to Seoul National University Hospital
within 7 days from disease onset between October 2002. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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According to the classification of Trial of Org 10172 in
Acute Stroke Treatment, amongst the chosen patients,
subjects with the following conditions were excluded from
this study: transient ischemic attack (n = 79; HTf = 0),
strokes attributable to small vessel disease (n = 221; HTf = 0),
or strokes of other determined etiology (n = 9; HTf = 1)
[12]. Patients without complete workups (n = 70; 10 with-
out initial MRI, 37 without follow-up MRI, 14 without
checking height, and 9 without laboratory workups) were
further excluded. The excluded 70 patients had more se-
vere stroke than included patients, and in-hospital death
rate of excluded patients was higher than that of included
patients. However, other demographic and cardiovascular
risk factors including the average and the distribution of
body mass index (BMI) were not different between two
groups (Additional file 1: Table S1). Therefore, our study
population consisted of a total of 365 patients with first-
ever acute ischemic stroke. The patient or the patient’s
next of kin was provided informed consent, and the study
was approved by the institutional review board at Seoul
National University Hospital (H-0911-065-301).
Baseline demographic and clinical information collected
at admission included age at onset, gender, body weight
and height at the time of admission, hypertension (a high
systolic blood pressure was defined as at least 140 mmHg
at discharge, and a diastolic blood pressure as at least
90 mmHg at discharge. Hypertension was defined as a high
systolic blood pressure or a high diastolic blood pressure or
as the current use of antihypertensive medication), diabetes
(previous use of antidiabetic medication, fasting blood
glucose > 7.0 mmol/L), hyperlipidemia (previous use of
lipid-lowering medication, total cholesterol > 6.0 mmol/L
at admission), smoking, previous use of antiplatelet or
anticoagulant medications, systolic and diastolic blood
pressure levels at admission, the level of blood glucose
and total cholesterol at admission, the initial National
Institute of Health Stroke Scale (NIHSS) score, and
thrombolytic or/and acute heparin treatment during acute
stage. BMI was calculated as weight (in kilograms) divided
by height (in meters squared), an obesity was defined
using the criteria of the World Health Organization
(WHO) Western Pacific Regional Office, which reflects a
different risk factors and body fat distribution in the Asian
Population [13].
All the participants underwent initial brain MRI before
the initiation of thrombolytic or antithrombotic therapy
(within 24 hours after admission) and follow-up brain
T2*-weighted gradient-recalled echo (GRE) MRI usually
within 1 week after occurrence of stroke (follow-up days:
mean ± SD, 6.7 ± 1.4). The MRI studies were performed
using 1.5-Tesla superconducting magnet (GE Healthcare,
Chalfont St. Giles, UK). The standardized MRI protocol
consisted of axial T2-weighted spin echo (repetitiontime/echo time, 2500 to 4500/80 to 112 ms; flip angle,
20˚; slice thickness, 5 mm; gap width, 2 mm) and
diffusion-weighted imaging (repetition time/echo time,
4000/73 ms; flip angle, 90˚; slice thickness, 5 mm; gap
width, 2 mm). The GRE images were obtained in the
axial plane with the following parameters: repetition
time/echo time, 500/15 ms; flip angle, 26°; matrix size,
256 × 192; slice thickness, 6 mm; and gap width, 2 mm.
The HTf was identified when follow-up GRE images
showed a low-signal area consistent with blood within
the acute ischemic lesion, according to the pre-specified
criteria [14]. White matter lesions (WMLs) were judged
as being absent, or present as punctuate, early confluent
or confluent abnormalities as seen on T2-weighted MR
images, according to the previously proposed method [15].
Early confluent or confluent lesions were designated as
advanced WMLs in this study. Microbleeds were defined
as focal homogenous areas with a diameter of 2 to 5 mm
as previously described [16,17].
The χ2 test and the Student t test were used to compare
categorical data and continuous data of the subjects,
respectively. The distribution of demographic, clinical,
and radiological variables were analyzed using χ2 test for
trends in proportion. The odds ratio (OR) and 95% confi-
dence interval (CI) for the HTf in each obesity status
were calculated using binary logic regression analyses.
For multivariable analyses, potential confounders were ad-
justed such as age, gender, hypertension, diabetes, hyper-
lipidemia, current smoking, initial NIHSS, thrombolysis,
acute heparin treatment, previous use of antiplatelet or
anticoagulant, stroke subtype, and the presence of advanced
WMLs and microbleeds. The adjusted OR and 95% CI
for the HTf or cerebral microbleeds were calculated by
multivariable analysis. Probability values were 2-tailed, and
P values < 0.05 were considered significant. All statistical
analyses were performed using SPSS 19.0 (SPSS Inc.,
Chicago, IL).
Results
Among 365 subjects, there were 246 men and 119
women. Subjects’ age ranged from 16 to 95 years, and
their mean age was 64.7 years. Average BMI of subjects
was 24.1 kg/m2. According to the WHO obesity criteria
for the Asian-Pacific Population, 94 patients (25.8%) were
classified as overweight (BMI, 23.0-24.9 kg/m2) and 146
(40%) were classified as obese (BMI, ≥ 25.0 kg/m2).
The HTf was noted in 59 patients (16.2%). Table 1
shows that BMI was significantly lower in subjects with
HTf (23.1 kg/m2) that in those without HTf (24.2 kg/m2).
The average of initial NIHSS score and the proportions
with cardioembolism and thrombolytic treatment were
greater in subjects with HTf. However, the average age,
glucose level, cholesterol level, and systolic and diastolic
blood pressure at admission, and the proportions of
Table 1 Baseline characteristics of patients with/without hemorrhagic transformation
Hemorrhagic transformation P value*
Absent (n = 306) Present (n = 59)
Demographic
Age, y 64.4 ± 12.4 66.3 ± 9.1 0.28
Gender, male 209 (68.3%) 37 (62.7%) 0.45
Body-mass index, kg/m2† 24.2 ± 3.2 23.1 ± 4.2 0.02
Clinical
Hypertension 182 (59.3%) 37 (62.7%) 0.67
Diabetes 93 (30.4%) 17 (28.8%) 0.88
Hyperlipidemia 47 (15.4%) 5 (8.5%) 0.22
Smoking 0.95
Never 192 (62.7%) 37 (62.7%)
Past 51 (16.7%) 9 (15.3%)
Current 63 (20.6%) 13 (22%)
Previous use of antiplatelet agents 9 (2.9%) 2 (3.4%) 0.69
Previous use of anticoagulation 9 (2.9%) 2 (3.4%) 0.69
Initial NIHSS score, median (IQR)† 8 (4–16) 3 (2–6) < 0.01
Acute treatment
Thrombolysis† 10 (3.3%) 14 (23.7%) < 0.01
Acute heparin treatment 98 (32%) 21 (35.6%) 0.65
Stroke subtype† < 0.01
Large artery atherosclerosis 135 (44.1%) 11 (18.6%)
Cardioembolism 81 (26.5%) 30 (50.8%)
Undetermined 90 (29.4%) 18 (30.5%)
Laboratory
Glucose, mmol/L 6.5 ± 2.1 6.9 ± 2.3 0.14
Total cholesterol, mmol/L 4.6 ± 1.0 4.6 ± 1.0 0.64
Systolic blood pressure, mmHg 152 ± 25 153 ± 27 0.87
Diastolic blood pressure, mmHg 88 ± 15 90 ± 17 0.39
Prolonged PT/aPTT (%) 36 (11.8%) 8 (13.6%) 0.66
Radiological
Advanced WMLs 76 (25.2%) 16 (28.1%) 0.63
Presence of microbleeds 68 (22.7%) 15 (26.3%) 0.61
Values are mean ± SD or number of participants (percentage).
NIHSS indicates National Institute of Health Stroke Scale; WMLs, white matter lesion; and IQR, Interquartile range.
*P values were obtained using the χ2 test for categorical data, and the Student t test for continuous data.
†P < 0.05.
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previous use of antiplatelet agents and anticoagulation,
acute heparin treatment, and the presence of advanced
WMLs and microbleeds were not different between those
with and without HTf. As the severity of obesity increased,
the incidence of HTf decreased, and the average of initial
NIHSS score also decreased (Table 2). The proportion of
subjects with hypertension increased according to the
severity of obesity.In the obese group, 15 (10.3%) subjects had HTf, and
compared with the normal weight group, the crude OR
for HTf in the obese group was 0.36 (95% CI, 0.18 to
0.71). After adjusting age, gender, hypertension, diabetes,
hyperlipidemia, atrial fibrillation (reflecting stroke sub-
type), smoking, initial NIHSS score (reflecting stroke se-
verity), thrombolytic and acute heparin treatment, and the
presence of advanced WMLs and microbleeds, a 61% risk
reduction of HTf in the obese group existed when
Table 2 The proportions of clinical radiological variables by the severity of obesity
Underweight Normal weight Overweight Obesity I Obesity II P for trend*
(< 18.5 kg/m2) (18.5-22.9 kg/m2) (23.0-24.9 kg/m2) (25.0-29.9 kg/m2) (≥ 30 kg/m2)
Variables (n = 365) n = 18 (4.9%) n = 107 (29.3%) n = 94 (25.8%) n = 134 (36.7%) n = 12 (3.3%)
Demographic
Age, y 71.1 ± 11.2 65.3 ± 12.7 65.2 ± 11.8 63.4 ± 11.1 61.0 ± 12.8 0.08
Gender, male 15 (83.3%) 73 (68.2%) 62 (66.0%) 88 (65.7%) 8 (66.7%) 0.67
Clinical
Hypertension† 7 (38.9%) 50 (46.7%) 58 (61.7%) 96 (71.6%) 8 (66.7%) < 0.01
Diabetes 3 (16.7%) 29 (27.1%) 32 (34.0%) 44 (32.8%) 2 (16.7%) 0.38
Hyperlipidemia 1 (5.6%) 13 (12.1%) 17 (18.1%) 20 (14.9%) 1 (8.3%) 0.55
Current smoking 7 (38.9%) 21 (19.6%) 23 (24.5%) 23 (17.2%) 2 (16.7%) 0.23
Initial NIHSS score† 5 (3–12) 5 (2–11) 4 (2–9) 3 (2–5) 3 (1–6) < 0.01
Thrombolysis 0 (0%) 9 (8.4%) 6 (6.4%) 9 (6.7%) 0 (0%) 0.61
Acute heparin treatment 9 (50%) 37 (34.6%) 31 (33%) 39 (29.1%) 3 (25%) 0.44
Antiplatelet Use 0 5 (4.7%) 4 (4.3%) 2 (1.5%) 0 0.48
Warfarin Use 0 2 (1.9%) 5 (5.3%) 4 (3.0%) 0 0.54
Radiological
Hemorrhagic transformation† 4 (22.2%) 26 (24.3%) 14 (14.9%) 14 (10.4%) 1 (8.3%) 0.04
Advanced WMLs 6 (35.3%) 26 (25%) 24 (26.1%) 35 (26.3%) 1 (8.3%) 0.6
Presence of microbleeds 2 (11.8%) 20 (19.4%) 21 (22.8%) 36 (27.1%) 4 (33.3%) 0.42
Values are mean ± SD, median (interquartile range), or number of participants (percentage).
NIHSS indicates National Institute of Health Stroke Scale; WMLs, white matter lesion.
*Based on χ2 test of trend across the severity of obesity.
†P < 0.05.
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ever, ORs for HTf or cerebral microbleeds did not decrease
in the overweight or the obese groups compared with the
normal group (Table 4).
Discussion and Conclusions
In the present study on patients with first-ever acute
ischemic stroke, we found that the occurrence of HTf
decreased according to the severity of obesity. In particular,Table 3 The risk of hemorrhagic transformation






Underweight (<18.5 kg/m2) 0.89 (0.27-2.94) 1.05 (0.28-3.96)
Normal (18.5-22.9 kg/m2) 1.00 (reference) 1.00 (reference)
Overweight (23.0-24.9 kg/m2) 0.55 (0.27-1.12) 0.48 (0.21-1.11)
Obesity (≥25 kg/m2) 0.36 (0.18-0.71)† 0.39 (0.17-0.87)†
HTf indicated hemorrhagic transformation; OR, odds ratio; and CI,
confidence interval.
*ORs (95% CI) were adjusted by age, gender, hypertension, diabetes,
hyperlipidemia, current smoking, initial NIHSS score, thrombolysis, acute
heparin treatment, stroke subtype, previous aspirin use, previous warfarin use,
and the presence of advanced WMLs and cerebral microbleeds.
†P < 0.05.obese subjects had a significantly decreased risk of HTf
when compared with the normal weight group, after
adjusting possible confounders including acute and previ-
ous treatment, and stroke severity and subtype.
Although our finding may seem controversial, the results
are not surprising. Considering HTf as poor prognostic
factor [3], the paradoxical effect of obesity on death after
ischemic stroke, the most deleterious outcome, has been
reported. In a Danish cohort of hospitalized acute strokeTable 4 The risk of hemorrhagic transformation or
cerebral microbleeds according to the severity of obesity





Underweight (<18.5 kg/m2) 0.71 (0.23-2.18) 0.65 (0.19-2.25)
Normal (18.5-22.9 kg/m2) 1.00 (reference) 1.00 (reference)
Overweight (23.0-24.9 kg/m2) 0.87 (0.48-1.57) 0.80 (0.42-1.52)
Obesity (≥25 kg/m2) 0.93 (0.55-1.57) 0.92 (0.51-1.69)
HTf indicated hemorrhagic transformation; OR, odds ratio; and CI,
confidence interval.
*ORs (95% CI) were adjusted by age, gender, hypertension, diabetes,
hyperlipemia, current smoking, initial NIHSS score, thrombolysis, acute heparin
treatment, stroke subtype, previous aspirin use, previous warfarin use, and the
presence of advanced WMLs.
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obesity [18]. The phenomenon was also noted in an ana-
lysis of a health and nutrition status survey in US individ-
uals, which showed that in aged population, obese stroke
survivors tend to have a lower risk of mortality than pa-
tients with a normal weight [19]. However, the mechanism,
which states that obesity increases the longevity in obese
patient after ischemic stroke is not clear. Based on our
findings and a review of the previous studies, HTf might
be related to “obesity paradox” in acute ischemic stroke.
In the present study it was observed that as increasing
of obesity severity, the proportion of cardioembolic stroke
and severe stroke (reflected by initial NIHSS score) de-
creased, despite of the elevated prevalence of hypertension
[20]. The incidence of HTf may be influenced by the
differences in these baseline characteristics among BMI
groups [10]. To reduce these confounding effects, we
conducted a multivariable analysis after adjusting various
possible confounders including the nature of stroke
(severity and subtype), acute and previous treatment. After
this adjustment, the presence of obesity independently
predicted the occurrence of HTf in our study. However,
the association between microbleeds and obesity was not
elucidated in this study with first-ever acute ischemic
stroke patients. Although microbleeds were suggested as a
risk factor for cerebral hemorrhage [21], they are not a
confirmed mediator of hemorrhagic transformation after
ischemic stroke. Compared with HTf, the weak relationship
between obesity and microbleeds may reflect the different
pathophysiology of HTf and cerebral microbleeds. While
the abrupt reperfusion after ischemic tissues elicits HTf, the
spontaneous rupture of injured small arterioles in brain
leads cerebral microbleeds.
For the cause of bleeding-obesity paradox, biological
explanations exist. First, alterations in circulating coagula-
tion factors have been suggested. Obesity has been related
to higher levels of multiple coagulation factors such as
factor VII, VIII, fibrinogen, and plasminogen activator
inhibitor-1 [22,23]. Second, in studies investigating the
association between BMI and platelet aggregation, patients
with BMI ≥ 25 kg/m2 were found to have suboptimal re-
sponse to antithrombotics than patients of normal weight
[24,25]. However, this phenomenon was evaluated in nor-
mal or coronary artery disease subjects, and not in acute
stroke patients. To clearly explain the “bleeding-obesity
paradox,” the assessment of the coagulability and drug re-
sponse in obese patient with acute ischemic stroke is
required.
In the present investigation, a number of points require
further clarification. First, due to the limitation of study
population, we focused on the relatively mild obese patients
and did not evaluate the phenomenon of “bleeding-obesity
paradox” in severely obese patients. To assess the effect of
BMI as a whole from underweight to severe obese, wesuggest that future studies on ischemic stroke patients
with widely-spread BMI should be undertaken. Second,
the long-term outcome of HTf, which is a major poor
prognostic factor in acute ischemic stroke, was not
evaluated in this study. Thus, we could not assess “obesity
paradox” per se in this study. Third, more severe stroke
patients were excluded because they could not undergo
brain MRI or did not have clinical information such as
height, and the effects of obesity on HTf in severe stroke
patients might not be evaluated completely.
The present study is unique because it documents the
better results about HTf in obese patients with acute
ischemic stroke, which persists after adjustment for acute
treatment and stroke severity and subtype. Thus, we
suggest the existence of a “bleeding-obesity paradox” in
ischemic stroke, and propose that the inverse association
between HTf and obesity in ischemic stroke may be
considered in the management of acute stroke patients.
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